Skip to main content
logo
Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
17.76
+0.09 (0.51%)
May 29, 2026, 4:00 PM EDT - Market closed

Nurix Therapeutics Income Statement

Millions USD. Fiscal year is Dec - Nov.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Revenue
71.7883.9854.5576.9938.6329.75
Revenue Growth (YoY)
27.23%53.95%-29.14%99.31%29.84%66.95%
Gross Profit
71.7883.9854.5576.9938.6329.75
Selling, General & Admin
55.752.7445.9442.93831.2
Research & Development
331.38316.9221.63189.15184.5116.43
Total Operating Expenses
387.08369.65267.58232.05222.49147.64
Operating Income
-315.3-285.67-213.03-155.06-183.87-117.89
Total Non-Operating Income (Expense)
20.7821.9719.7311.123.510.82
Pretax Income
-207.35-263.7-193.3-143.95-180.36-117.06
Provision for Income Taxes
0.760.760.27--0.13
Net Income
-295.28-264.46-193.57-143.95-180.36-117.19
Net Income to Common
-295.28-264.46-193.57-143.95-180.36-117.19
Shares Outstanding (Basic)
938767544943
Shares Outstanding (Diluted)
938767544943
Shares Change (YoY)
25.60%29.12%23.52%11.79%13.32%173.68%
EPS (Basic)
-3.16-3.05-2.88-2.65-3.71-2.73
EPS (Diluted)
-3.16-3.05-2.88-2.65-3.71-2.73
Shares Outstanding
103.4101.8175.8748.7247.1744.66
Free Cash Flow
-126.35-263.47-182.14-89.48-172.05-90.03
Free Cash Flow Per Share
-1.35-3.04-2.71-1.65-3.54-2.10
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-439.26%-340.16%-390.52%-201.41%-476.01%-396.25%
Profit Margin
-289.93%-314.90%-354.85%-186.98%-466.93%-393.93%
FCF Margin
-176.02%-313.73%-333.91%-116.23%-445.42%-302.61%
EBITDA
-305.38-266.81-196.6-141.41-173.06-111.8
EBITDA Margin
-425.44%-317.71%-360.41%-183.68%-448.03%-375.81%
EBIT
-315.3-285.67-213.03-155.06-183.87-117.89
EBIT Margin
-439.26%-340.16%-390.52%-201.41%-476.01%-396.25%
Effective Tax Rate
-0.37%-0.29%-0.14%0.00%0.00%-0.11%
SEC Filings: 10-K · 10-Q